Attention-Deficit Hyperactivity Disorder Severity Reduced With SDX/d-MPH
Key Point: SDX/d-MPH was well tolerated and had no safety concerns in the treatment of ADHD severity in children. Attention-deficit hyperactivity disorder (ADHD) severity in children was significantly reduced when treated with serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH), according to research presented at Psych Congress 2022 held from September 17 to 20, 2022, in New Orleans, Louisiana.
Other Articles in this Edition
The Adderall Shortage is Causing Mass Chaos for Patients, Doctors and Pharmacies
5 Common Signs of ADHD in Women, According to Experts
Kids with disabilities face off-the-books school suspensions
Attention-Deficit Hyperactivity Disorder Severity Reduced With SDX/d-MPH
Antidepressant use during pregnancy not linked to ADHD, autism: study
Study of adults with ADHD links childhood clumsiness to a higher likelihood of being bullied
Prevalence of ADHD Higher in Pediatric Patients With Mild Head Trauma
Researchers identify shared and differentiating genetic variants for ADHD and autism
Patient Case #1: Co-Managing ADHD
Investigators Look at How ADHD, ODD Dimensions Relate to Impulsivity
How To Explain Your Child’s ADHD To Older-Generation Family Members